You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
MBio is developing the system for use with human host-response biomarker assays that can be used to identify gravely ill or highly contagious individuals.
The Swedish firms plans to launch clinical performance studies in support of getting CE marking for its QuickMIC system.
The panel will aid in the diagnosis of patients with respiratory symptoms in about an hour by differentiating SARS-CoV-2 from other bacterial and viral pathogens.
Some believe that more could be done to help deliver diagnostics to the European market.
InfanDx is taking the lead on the project and will be joined by researchers from University Hospital Essen, Clinic for Pediatrics I, and Furtwangen University.
The funding, part of a larger initiative by Genome Canada, will support two studies in British Columbia that will evaluate genomics in healthcare.
The Bill & Melinda Gates Foundation will also provide support to winners of the challenge, which may include a grant of up to $500,000.
The funding comes from the Bill and Melinda Gates Foundation, which previously provided the company with $500,000 for the test's initial development.
The company will conduct a clinical study examining the proteins BCL6 and SIRT1 as biomarkers of endometriosis and endometrial receptivity.
The agency is also hosting a portal for submissions and inquiries as part of the newly created Medical Countermeasures Taskforce.
An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.
Framingham, Massachusetts-based Kephera's tests is intended to be used to differentiate neurocysticercosis from other causes of seizures in patients.
BIOASTER and Mologic will develop and clinically evaluate a test prototype for detecting O. volvulus antibodies in blood with high specificity.
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
Under a contract with BARDA, First Light is developing a digital imaging-based diagnostics platform, as well as tests for anthrax and urinary tract infections.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
Apatagen is developing the aptamer-based test to diagnose human carriers of pork tapeworm and prevent neurocysticercosis, which causes adult-onset epilepsy.
The companies are developing a blood-based assay for differentiating lung cancer from benign disease in patients testing positive in low-dose CT screens.
The grants were awarded through the organization's Diagnostic Accelerator, a partnership between the charity and various philanthropic partners.
The Dutch companies will use sequencing- and machine learning-based methods to quantify genomic instability-causing mutations in blood cells.